

Changes in Migraine-related Outcomes and Functioning at 1 Year: Results of the Longitudinal OVERCOME (US) Study

Dawn C. Buse¹, Richard B. Lipton^{1,2}, Ali Sheikhi Mehrabadi^{3†}, Anthony J. Zagar^{3†}, Armen Zakharyan⁴, Sait Ashina⁵, Robert E. Shapiro⁶, Gilwan Kim³, Robert A. Nicholson³, E. Jolanda Muenzel³

¹Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, United States of America

²Montefiore Headache Center, Bronx, New York, United States of America

³Eli Lilly and Company, Indianapolis, Indiana, United States of America

⁴TechData Service Company, LLC, King of Prussia, Pennsylvania, United States of America

⁵Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, and Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

⁶Department of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, Vermont, United States of America

[†]Authors were employees of Eli Lilly and Company at time of study

E. Jolanda Muenzel,

Eli Lilly and Company, Lilly Corporate Center,

Indianapolis, IN 46284, USA

jolanda.muenzel@lilly.com

SUPPLEMENTAL MATERIAL

Table S1. Study details for AMS I and II, AMPP, CaMEO and MAST.

Study	Participants	People with active migraine	Delivery	Study design	Follow up
AMS I	20,468	2479	Mail	Cross-sectional, single cohort	N/A
AMS II	29,727	3738	Mail	Cross-sectional, single cohort	N/A
AMPP	162,576	18,968	Mail	Longitudinal (annually)	5 years (2004–2009)
CaMEO	80,783	16,789	Web-based survey	Longitudinal (Quarterly)	1 year (2012–2013)
MAST	117,150	18,353	Web-based survey	Longitudinal	6 months (2017–2018)

AMS, American Migraine Study; AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes; MAST, Migraine in America Symptoms and treatment; N/A, Not applicable

Table S2. Variable response types

Domain	Variable at baseline	Response type
Sociodemographic	Age	Continuous
	Sex	Binary (Male/Female)
	Race	Categorical (White only, Black only, Other [Asian American only, American Indian only, Native Hawaiian only, Other, two or more races])
	Ethnicity	Binary (Hispanic/Not Hispanic)
	Education	Categorical (High School/Some College/College Degree)
	Employment	Binary (Yes/No)
	Healthcare insurance	Binary (Yes/No)
	Urban/Rural	Binary (Urban/Rural)
	Region	Categorical (Northeast/Midwest/South/West)
	Household income	Ordinal (<\$50,000/\$50,000-\$99,999/>100,000+)
	Marital status	Binary (Yes/No)
	Children under 18 years living in the household	Binary (Yes/No)
Comorbidities	Presence of self-reported comorbidity that contraindicates triptan use	Binary (Yes/No)
	Number of self-reported cardiovascular comorbidities	Ordinal (0/1/2+)
	Number of self-reported joint or pain comorbidities	Ordinal (0/1/2+)
	Psychiatric comorbidity	Ordinal (0/1/2/3)

	Digestive comorbidity	Binary (Yes/No)
	PHQ-4 total score	Continuous (Range 0–12)
	Sleep apnea	Binary (Yes/No)
	Allergies	Binary (Yes/No)
	Asthma	Binary (Yes/No)
	Framingham risk score	Binary (Yes/No)
Health Status	Marijuana use	Binary (Yes/No)
	BMI	Categorical (Obese/ Overweight/ Underweight/Normal)
	Tobacco use	Binary (Yes/No)
Migraine-related	Years with migraine	Continuous
	MSSS score	Continuous (Range: 0–21)
	Ictal cutaneous allodynia	Ordinal (ASC-12 score: None 0–2, Mild 3–5, Moderate 6–8, Severe 9+)
	Headache pain intensity score	Continuous (Range: 0–10)
	Frequency of headaches	Ordinal (Headache days/month: 0–3/4–7/8–14/≥15)
	Migraine diagnosis class	Categorical (Migraine diagnosis only/Other headache diagnosis only/Migraine and other headache diagnosis/No diagnosis)
Treatment-related	Currently taking recommended acute prescription medication for migraine	Binary (Yes/No)
	mTOQ	Ordinal (Very poor/Poor/Moderate/Maximum treatment efficacy)
	Currently taking OTC pain-relieving medications for migraine	Binary (Yes/No)

	Currently taking any acute medication for migraine	Binary (Yes/No)
	Currently taking any preventive medication for migraine	Binary (Yes/No)
	Ever having used preventive medication for migraine	Binary (Yes/No)
	Candidate for migraine acute and preventive medications	Categorical (Candidate for acute/candidate for preventive/candidate for acute and preventive/not a candidate)
Healthcare utilization behavior	Ever hesitated to seek care for migraine	Binary (Yes/No)
	Ever having talked to a healthcare provider about migraine	Binary (Yes/No)
	Sought care for migraine in the previous 12 months	Binary (Yes/No)
	Most specialized level of care	Categorical (Emergency Care/Primary Care/Specialty Care)
Patient-reported outcomes	MSQ-RFR score	Continuous (Range 0-100)
	MSQ-RFP score	Continuous (Range 0-100)
	MSQ-EF score	Continuous (Range 0-100)
	Migraine symptoms interfere with sleep	Ordinal (All of the time/Most of the time/A good bit of the time/A little bit of the time/Some of the time/ None of the time)
	Migraine symptoms interfere with mood	Ordinal (All of the time/Most of the time/A good bit of the time/A little bit of the time/Some of the time/ None of the time)

	Migraine symptoms interfere with driving	Ordinal (All of the time/Most of the time/A good bit of the time/A little bit of the time/Some of the time/ None of the time)
	Migraine symptoms interfere with exercise	Ordinal (All of the time/Most of the time/A good bit of the time/A little bit of the time/Some of the time/ None of the time)
	MIDAS	Ordinal (MIDAS score: Little or None 0–5, Mild 6–10, Moderate 11–20, Severe 21+)
	MIBS-4	Ordinal (MIBS-4 score: None 0, Mild 1-2, Moderate 3-4, Severe 5+)
	WPAI	Absenteeism – Binary (Yes/No)
		Presenteeism – Binary (Yes/No)
		Activity Loss – Binary (Yes/No)
		Work productivity loss – Binary (Yes/No)
	Hiding migraine	From family and friends – Binary (Yes/No)
		At work – Binary (Yes/No)
	Migraine-related impairment	Categorical (I work or function normally, working ability or activity impaired to some degree, working ability or activity severely impaired but no bed rest required, bed rest required)
	Migraine-related stigma	Ordinal (MiRS questionnaire: Never/Rarely or Sometimes/Often or very often)

ASC-12, 12-item Allodynia Symptom Checklist-12; BMI, body mass index; MIBS-4, 4-item Migraine Interictal Burden Scale, MIDAS, Migraine Disability Assessment Scale; MiRS, Migraine-Related Stigma Questionnaire; MSQ-RFR, Migraine-Specific Quality of Life Questionnaire–Role-Function-Restrictive; MSQ-RFP, Migraine-Specific Quality of Life Questionnaire–Role-Function-Preventive; MSQ-EF, Migraine-Specific Quality of Life Questionnaire–Emotional function; MSSS, Migraine Symptoms Severity Scale; mTOQ, Migraine Treatment Optimization Questionnaire; OTC, over-the-counter; PHQ-4, 4- item Patient Health Questionnaire for Anxiety and Depression; WPAI, Work Productivity Index.

